

Runlin Gao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3556692/publications.pdf>

Version: 2024-02-01

120
papers

3,667
citations

236925

25
h-index

149698

56
g-index

120
all docs

120
docs citations

120
times ranked

4292
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality of primary health care in China: challenges and recommendations. <i>Lancet, The</i> , 2020, 395, 1802-1812.	13.7	391
2	A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Effects of Qili Qiangxin Capsules in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1065-1072.	2.8	267
3	1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. <i>Lancet, The</i> , 2016, 387, 1277-1289.	13.7	253
4	A Phase II, Randomized, Double-Blind, Multicenter, Based on Standard Therapy, Placebo-Controlled Study of the Efficacy and Safety of Recombinant Human Neuregulin-1 in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1907-1914.	2.8	238
5	Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2298-2309.	2.8	228
6	2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. <i>Lancet, The</i> , 2017, 390, 760-772.	13.7	163
7	Three-Year Outcomes With the Absorb Bioresorbable Scaffold. <i>Circulation</i> , 2018, 137, 464-479.	1.6	152
8	Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2863-2874.	2.8	125
9	Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). <i>European Heart Journal</i> , 2020, 41, 3715-3728.	2.2	121
10	Long-term in vivo corrosion behavior, biocompatibility and bioresorption mechanism of a bioresorbable nitrided iron scaffold. <i>Acta Biomaterialia</i> , 2017, 54, 454-468.	8.3	110
11	Impact of Operator Experience and Volume on Outcomes After Left Main Coronary Artery Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2086-2093.	2.9	97
12	Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2664-2678.	2.8	93
13	Drug-Coated Balloon Versus Drug-Eluting Stent for Small-Vessel Disease. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2381-2392.	2.9	81
14	Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up. <i>JAMA Cardiology</i> , 2019, 4, 1261.	6.1	71
15	Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity. <i>Circulation</i> , 2018, 137, 2231-2245.	1.6	68
16	Predictive value of inflammatory factors on contrast-induced acute kidney injury in patients who underwent an emergency percutaneous coronary intervention. <i>Clinical Cardiology</i> , 2017, 40, 719-725.	1.8	63
17	Long-Term Efficacy of Biodegradable Metal-Polymer Composite Stents After the First and the Second Implantations into Porcine Coronary Arteries. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 15703-15715.	8.0	50
18	In vivo degradation and endothelialization of an iron bioresorbable scaffold. <i>Bioactive Materials</i> , 2021, 6, 1028-1039.	15.6	45

#	ARTICLE	IF	CITATIONS
19	Coronary Artery Bypass Graft Surgery and Percutaneous Coronary Interventions in Patients With Unprotected Left Main Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1102-1111.	2.9	42
20	Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2017, 38, 2559-2566.	2.2	42
21	Biodegradable Polymer-Based Sirolimus-Eluting Stents With Differing Elution and Absorption Kinetics. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2249-2258.	2.8	40
22	Implications of N-terminal pro-B-type natriuretic peptide in patients with three-vessel disease. <i>European Heart Journal</i> , 2019, 40, 3397-3405.	2.2	39
23	Selective stent placement versus balloon angioplasty for renovascular hypertension caused by Takayasu arteritis: Two-year results. <i>International Journal of Cardiology</i> , 2016, 205, 117-123.	1.7	35
24	Comparison of Physician Visual Assessment With Quantitative Coronary Angiography in Assessment of Stenosis Severity in China. <i>JAMA Internal Medicine</i> , 2018, 178, 239.	5.1	34
25	Predictive value of in-hospital white blood cell count in Chinese patients with triple-vessel coronary disease. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 872-882.	1.8	31
26	PDLLA-Zn-nitrided Fe bioresorbable scaffold with 53- $\frac{1}{4}$ m-thick metallic struts and tunable multistage biodegradation function. <i>Science Advances</i> , 2021, 7, .	10.3	31
27	Implications of Periprocedural Myocardial Biomarker Elevations and Commonly Used MI Definitions After Left Main PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1623-1634.	2.9	27
28	High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort. <i>Cardiovascular Diabetology</i> , 2022, 21, 46.	6.8	27
29	Rational and design of a stepped-wedge cluster randomized trial evaluating quality improvement initiative for reducing cardiovascular events among patients with acute coronary syndromes in resource-constrained hospitals in China. <i>American Heart Journal</i> , 2015, 169, 349-355.	2.7	24
30	Percutaneous Transluminal Angioplasty for Symptomatic Pulmonary Stenosis in Takayasu Arteritis. <i>Journal of Rheumatology</i> , 2014, 41, 1856-1862.	2.0	22
31	Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study. <i>Cardiovascular Diabetology</i> , 2021, 20, 143.	6.8	22
32	Risk assessment and aspirin use in Asian and Western populations. <i>Vascular Health and Risk Management</i> , 2010, 6, 943.	2.3	21
33	Clinical blood pressure responses to daily ambient temperature exposure in China: An analysis based on a representative nationwide population. <i>Science of the Total Environment</i> , 2020, 705, 135762.	8.0	21
34	Liver Fibrosis Scoring Systems as Novel Tools for Predicting Cardiovascular Outcomes in Patients Following Elective Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2021, 10, e018869.	3.7	20
35	Symptom-Onset-To-Balloon Time, ST-Segment Resolution and In-Hospital Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention in China: From China Acute Myocardial Infarction Registry. <i>American Journal of Cardiology</i> , 2016, 118, 1334-1339.	1.6	19
36	Stenting for middle aortic syndrome caused by Takayasu arteritis: Immediate and long-term outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 623-631.	1.7	19

#	ARTICLE	IF	CITATIONS
37	Two-year follow-up of a randomized multicenter study comparing a drug-coated balloon with a drug-eluting stent in native small coronary vessels: The RESTORE Small Vessel Disease China trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 587-597.	1.7	19
38	Sedentary Behavior and the Risk of Depression in Patients With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2018, 121, 1456-1460.	1.6	18
39	D-dimer as a thrombus biomarker for predicting 2-year mortality after percutaneous coronary intervention. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232090430.	2.5	18
40	Current status of percutaneous coronary intervention in China. <i>Heart</i> , 2010, 96, 415-418.	2.9	17
41	Additional value of deep learning computed tomographic angiography-based fractional flow reserve in detecting coronary stenosis and predicting outcomes. <i>Acta Radiologica</i> , 2022, 63, 133-140.	1.1	16
42	Predicting In-Hospital Mortality in Patients With Acute Coronary Syndrome in China. <i>American Journal of Cardiology</i> , 2017, 120, 1077-1083.	1.6	15
43	Usefulness of the SYNTAX score II to validate 2-year outcomes in patients with complex coronary artery disease undergoing percutaneous coronary intervention: A large single-center study. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 40-47.	1.7	15
44	Six-month adherence to Statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes. <i>Lipids in Health and Disease</i> , 2017, 16, 155.	3.0	14
45	Implications of Hyperuricemia in Severe Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2019, 123, 558-564.	1.6	14
46	Effects of long-term psychological intervention on blood pressure and health-related quality of life in patients with hypertension among the Chinese working population. <i>Hypertension Research</i> , 2017, 40, 999-1007.	2.7	13
47	A New Risk Factor Profile for Contrast-Induced Acute Kidney Injury in Patients Who Underwent an Emergency Percutaneous Coronary Intervention. <i>Angiology</i> , 2018, 69, 523-531.	1.8	12
48	Impact of Prior Use of Four Preventive Medications on Outcomes in Patients Hospitalized for Acute Coronary Syndrome—Results from CPACS-2 Study. <i>PLoS ONE</i> , 2016, 11, e0163068.	2.5	12
49	New Insights Into Long- Versus Short-Term Dual Antiplatelet Therapy Duration in Patients After Stenting for Left Main Coronary Artery Disease: Findings From a Prospective Observational Study. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, 101161CIRCINTERVENTIONS121011536.	3.9	12
50	Use of cardiovascular prevention treatments after acute coronary syndrome in China and associated factors. <i>International Journal of Cardiology</i> , 2017, 241, 444-449.	1.7	11
51	Efficacy and Safety of the Absorb Bioresorbable Vascular Scaffold in Females and Males. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1881-1890.	2.9	11
52	Impact of Diabetes Mellitus on Percutaneous Coronary Intervention in Chinese Patients: A Large Single-Center Data. <i>Angiology</i> , 2018, 69, 540-547.	1.8	11
53	First-in-man study of a thinner-strut sirolimus-eluting bioresorbable scaffold (FUTURE): Three-year clinical and imaging outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 648-657.	1.7	11
54	China Tongxinluo Study for myocardial protection in patients with Acute Myocardial Infarction (CTS-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical trial. <i>American Heart Journal</i> , 2020, 227, 47-55.	2.7	11

#	ARTICLE	IF	CITATIONS
55	Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 47-56.	2.6	10
56	Efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease undergoing percutaneous coronary intervention. <i>Current Medical Research and Opinion</i> , 2020, 36, 1739-1745.	1.9	10
57	Thinner Strut Sirolimus-Eluting BRS Versus EES in Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1450-1462.	2.9	10
58	Treatment and outcomes of acute coronary syndromes in women: An analysis of a multicenter quality improvement Chinese study. <i>International Journal of Cardiology</i> , 2017, 241, 19-24.	1.7	9
59	Prognostic Value of Plasma Big Endothelin-1 Level among Patients with Three-Vessel Disease: A Cohort Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 959-969.	2.0	9
60	Susceptible gene polymorphism in patients with three-vessel coronary artery disease. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 172.	1.7	9
61	Atorvastatin induces autophagy of mesenchymal stem cells under hypoxia and serum deprivation conditions by activating the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. <i>Chinese Medical Journal</i> , 2014, 127, 1046-51.	2.3	9
62	Impact of unknown diabetes and prediabetes on clinical outcomes in non-diabetic Chinese patients after a primary coronary intervention. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 644-651.	2.6	8
63	Impact of Lipoprotein(a) on Long-Term (Mean 6.2 Years) Outcomes in Patients With Three-Vessel Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2020, 125, 528-533.	1.6	8
64	Percutaneous transluminal angioplasty with selective stenting for the treatment of renal artery stenosis caused by fibromuscular dysplasia: 18 years' experience from the China Center for Cardiovascular Disease. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 641-647.	1.7	8
65	Superselective adrenal arterial embolization for idiopathic hyperaldosteronism: 12-month results from a proof-of-principle trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 976-981.	1.7	8
66	The efficacy of renal artery stent combined with optimal medical therapy in patients with severe atherosclerotic renal artery stenosis. <i>Current Medical Research and Opinion</i> , 2016, 32, 3-7.	1.9	7
67	Subclavian artery stenting for coronary-subclavian steal syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 601-608.	1.7	7
68	Association of body mass index with mortality in Chinese patients after percutaneous coronary intervention: A large single-center data. <i>Cardiovascular Therapeutics</i> , 2017, 35, e12271.	2.5	7
69	Factors attributed to the higher in-hospital mortality of ST elevation myocardial infarction patients admitted during off-hour in comparison with those during regular hour. <i>PLoS ONE</i> , 2017, 12, e0175485.	2.5	7
70	Association of renal insufficiency with treatments and outcomes in patients with acute coronary syndrome in China. <i>International Journal of Cardiology</i> , 2021, 323, 7-12.	1.7	7
71	Body mass index and mortality in patients with severe coronary artery diseases: A cohort study from China. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 448-454.	2.6	7
72	Real-world outcomes of different treatment strategies in patients with diabetes and three-vessel coronary disease: a mean follow-up 6.3 years study from China. <i>Cardiovascular Diabetology</i> , 2021, 20, 16.	6.8	7

#	ARTICLE	IF	CITATIONS
73	Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 873-882.	2.0	7
74	Optimum technique to reduce risk of stent thrombosis – Authors' reply. <i>Lancet</i> , The, 2016, 388, 127-128.	13.7	6
75	Carotid artery stenting followed by open heart surgery in 323 patients: One-year results and influencing factors. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 632-638.	1.7	6
76	The PRECISE-DAPT score and 5-year outcomes after percutaneous coronary intervention: a large-scale, real-world study from China. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 812-820.	4.0	6
77	Similar Inflammatory Biomarkers Reflect Different Platelet Reactivity in Percutaneous Coronary Intervention Patients Treated With Clopidogrel: A Large-Sample Study From China. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 736466.	2.4	6
78	Association of <i>NPC1L1</i> and <i>HMGR</i> Gene Polymorphisms with Major Adverse Cardiac and Cerebrovascular Events in Patients with Three-Vessel Disease. <i>Human Gene Therapy</i> , 2021, 32, 581-588.	2.7	5
79	The hospital management practices in Chinese county hospitals and its association with quality of care, efficiency and finance. <i>BMC Health Services Research</i> , 2021, 21, 449.	2.2	5
80	Comparison of Short- and Medium-Term Clinical Outcomes between Transradial Approach and Transfemoral Approach in a High-Volume PCI Heart Center in China. <i>PLoS ONE</i> , 2015, 10, e0118491.	2.5	5
81	Effect of NPC1L1 and HMGR Genetic Variants With Premature Triple-Vessel Coronary Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 704501.	2.4	5
82	Prognostic Impact of Left Ventricular Ejection Fraction in Patients With Moderate Aortic Regurgitation: Potential Implications for Treatment Decision-Making. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 800961.	2.4	5
83	An unrecognised presentation of Takayasu arteritis: superficial femoral artery involvement. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 83-87.	0.8	5
84	Prognostic value of modified model for end-stage liver disease scores in patients with significant tricuspid regurgitation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2023, 9, 227-239.	4.0	5
85	Association of Baseline Smoking Status with Long-Term Prognosis in Patients Who Underwent Percutaneous Coronary Intervention: Large Single-Center Data. <i>Journal of Interventional Cardiology</i> , 2019, 2019, 1-9.	1.2	4
86	Impact of baseline estimated glomerular filtration rate on inhospital outcomes of patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: A China acute myocardial infarction registry study. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 793-799.	1.7	4
87	The sex difference in 6-month MACEs and its explaining variables in acute myocardial infarction survivors: Data from CPACS-3 study. <i>International Journal of Cardiology</i> , 2020, 311, 1-6.	1.7	4
88	Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 768190.	2.4	4
89	PLATINUM China: A prospective, randomized investigation of the platinum chromium everolimus-eluting stent in de novo coronary artery lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 716-723.	1.7	3
90	Comparison of two biodegradable-polymer-based sirolimus-eluting stents with varying elution and absorption kinetics in patients with acute myocardial infarction: A subgroup analysis of the PANDA III trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 520-527.	1.7	3

#	ARTICLE	IF	CITATIONS
91	I-CARE randomized clinical trial integrating depression and acute coronary syndrome care in low-resource hospitals in China: Design and rationale. <i>American Heart Journal</i> , 2018, 202, 109-115.	2.7	3
92	Prognostic Significance of In-hospital Acquired Thrombocytopenia in Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>American Journal of the Medical Sciences</i> , 2019, 358, 19-25.	1.1	3
93	Prognostic Value of the PARIS Thrombotic Risk Score for 2-Year Mortality After Percutaneous Coronary Intervention. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961985363.	1.7	3
94	The Effective and Safe Way to Use Crusade Microcatheter-Facilitated Reverse Wire Technique to Solve Bifurcated Lesions with Markedly Angulated Target Vessel. <i>Journal of Interventional Cardiology</i> , 2019, 2019, 1-7.	1.2	3
95	Two-year safety evaluation of a biodegradable polymer sirolimus-eluting stent with increased drug elution and polymer absorption kinetics in complex patient and lesion cohort. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 206-215.	1.7	3
96	Radial versus femoral approach for rotational atherectomy. <i>Coronary Artery Disease</i> , 2020, 31, 393-395.	0.7	3
97	Associations Between Education Level and In-hospital Treatment and Outcomes Among Acute Coronary Syndrome in China. <i>American Journal of the Medical Sciences</i> , 2021, 361, 253-260.	1.1	3
98	Validation of the long-term prognostic capability of the SYNTAX score II in patients undergoing biodegradable polymer-based Sirolimus-eluting stents: 2-year outcomes from the PANDA III trial. <i>International Journal of Cardiology</i> , 2020, 309, 27-32.	1.7	3
99	Prevalence, Predictors, and Impact of Coronary Artery Ectasia in Patients With Atherosclerotic Heart Disease. <i>Angiology</i> , 2023, 74, 47-54.	1.8	3
100	The interval between carotid artery stenting and open heart surgery is related to perioperative complications. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 564-569.	1.7	2
101	Influences of Smoking Status on Effectiveness of Cytochrome P450 Enzyme System Metabolized Medications in Reducing In-Hospital Death in 14 658 Patients With Acute Myocardial Infarction: Data From CPACS-3 Study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 418-424.	2.0	2
102	Prognostic value of the GRACE discharge score for predicting the mortality of patients with stable coronary artery disease who underwent percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 550-557.	1.7	2
103	External carotid artery stenting in patients with ipsilateral internal carotid artery occlusion: Perioperative and 12-month follow-up. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 982-987.	1.7	2
104	Therapeutic Decision-Making and Outcomes in Elderly Patients With Severe Symptomatic Aortic Stenosis: Prognostic Implications of Elderly Patients' Initial Decisions. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 696763.	2.4	2
105	5-Year Clinical Outcomes of Successful Recanalisation for Coronary Chronic Total Occlusions in Patients With or Without Type 2 Diabetes Mellitus. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 691641.	2.4	2
106	Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>Global Heart</i> , 2021, 16, 89.	2.3	2
107	Endovascular therapy for AngioSeal TM -related acute limb ischemia: Perioperative and long-term results. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 609-615.	1.7	1
108	Safety and feasibility of simultaneous endovascular therapy for supraaortic multivessel stenosis in 256 Chinese patients. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 846-850.	1.7	1

#	ARTICLE	IF	CITATIONS
109	A modified predilation, sizing, and postdilation scoring system for patients undergoing metallic drug-eluting stent implantations. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 558-564.	1.7	1
110	The effect of stenting on blood pressure in hypertensive patients with symptomatic proximal subclavian or vertebral artery stenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 633-640.	1.7	1
111	Chronic kidney disease and the outcomes of fibrinolysis for ST-segment elevation myocardial infarction: A real-world study. <i>PLoS ONE</i> , 2021, 16, e0245576.	2.5	1
112	Long-Term Outcomes of Single-Vessel Percutaneous Coronary Intervention on Culprit Vessel vs. Multivessel Percutaneous Coronary Intervention in Non-ST-Segment Elevation Acute Coronary Syndrome Patients With Multivessel Coronary Artery Disease. <i>Circulation Journal</i> , 2021, 85, 185-193.	1.6	1
113	Prognostic value of GRACE and CHA2DS2-VASc score among patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Annals of Medicine</i> , 2021, 53, 2217-2226.	3.8	1
114	One-year outcomes of percutaneous renal denervation for the treatment of resistant hypertension: the first Chinese experience. <i>Chinese Medical Journal</i> , 2014, 127, 1003-7.	2.3	1
115	Bioresorbable scaffolds for coronary artery disease: current status and future prospective. <i>Chinese Medical Journal</i> , 2014, 127, 1141-8.	2.3	1
116	A glance at clinical research in interventional cardiology presented to CIT 2015. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 694-695.	1.7	0
117	Three-year outcome of everolimus-eluting bioresorbable vascular scaffold versus everolimus-eluting metallic stents: a comprehensive updated meta-analysis of randomized controlled trials. <i>Expert Review of Medical Devices</i> , 2019, 16, 421-427.	2.8	0
118	CCI and CIT 2020—A special year of the special issue. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 532-533.	1.7	0
119	Quality improvement in the cardiovascular catheterization laboratory in China. <i>Chinese Medical Journal</i> , 2014, 127, 1001-2.	2.3	0
120	Long-term effects of baseline on-treatment platelet reactivity in patients with acute coronary syndrome and thrombocytopenia undergoing percutaneous coronary intervention. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210817.	1.0	0